top of page

Search Results

Results found for "pain modeling"

  • Charlotte Crauwels: Designing Hybrid GPCRs with Computational Protein Engineering | Dr. GPCR Ecosystem

    Crauwels emphasizes the critical role of well-annotated experimental data for training predictive models Her work integrates bioinformatics, protein modeling, and experimental collaboration to support GPCR can significantly improve computational models. “Garbage in, garbage out—computational models depend entirely on the quality of experimental data.” the models.

  • Graciela Pineyro: Resilience, Lab Life, and the Zoom Effect | Dr. GPCR Ecosystem

    of opioid receptors and is currently focusing on the pharmacology of cannabinoids in the context of pain

  • GPCR Assay Strategy, Bias, and Translational Drug Discovery | Dr. GPCR Ecosystem

    realities of using fluorescence-based assays, the challenge of translating in vitro pharmacology to in vivo models How integrating antibody-based modalities has expanded options for hard-to-drug GPCR targets. Teams expanding into antibody or biologic modalities for challenging GPCR targets.

  • Dr. Sai Prasad Pydi | Dr. GPCR Ecosystem

    The main target of Dr. His laboratory uses knock-out and transgenic mouse models, along with different cell culture systems,

  • Dr. Tobi Langenhan | Dr. GPCR Ecosystem

    to the University of Oxford on a 4-year Wellcome Trust Scholarship in Neuroscience, through which I gained I work with invertebrate animal models (mainly D. melanogaster) and in vitro techniques to pick apart adhesion GPCRs, and extends to the development of novel screening approaches to identify pharmacological modulators

  • Terry Hebert: How Cellular Background and Localization Influence GPCR Function | Dr. GPCR Ecosystem

    Terry Hebert explains why studying GPCRs in HEK293 cells misses critical biology — and how iPSC-derived models cell type, and is now deploying them in iPSC-derived cardiomyocytes and patient-specific stem cell models failure of a biased agonist exposed the cost of oversimplifying that signaling landscape. iPSC-Derived Models biosensors revealing cell-type-dependent outputs 10:54 Building the toolkit — biosensors, iPSC-derived models and his team are working on understanding receptor signaling in specialized cellular environments to gain

  • GPCR Retreat | Dr. GPCR Ecosystem

    The main goal of the GPCR Retreat is to provide a venue for students, post-doctoral fellows, and principal University in Australia, one of the pioneers in the medicinal chemistry, computational and mathematical modelling scientists working in the arenas of structure and signaling, neuroscience, cancer, translational and model

  • Dr. Kathleen Caron | Dr. GPCR Ecosystem

    steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models coupled receptors and receptor activity modifying proteins in vascular biology, the Caron laboratory has gained

  • Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky | Dr. GPCR Ecosystem

    steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models coupled receptors and receptor activity modifying proteins in vascular biology, the Caron laboratory has gained Slosky characterized a new class of β-arrestin biased allosteric modulators (BAMs) for the neurotensin Critically, these ligands reduce addiction-associated behaviors in animal models without the side effects

  • Dr. JoAnn Trejo | Dr. GPCR Ecosystem

    Trejo’s research program is to gain a thorough and mechanistic understanding of processes that control critical expertise, and rigorous approaches to examine PAR1 function using human cultured cells and mouse models

  • Dr. Jean Martin Beaulieu | Dr. GPCR Ecosystem

    In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia The Beaulieu group is presently investigating how cell surface express proteins can act as allosteric modulators Translational validation is important to validate findings obtained from experimental models research

  • Fiona Marshall: Three Decades Inside GPCR Drug Discovery | Dr. GPCR Ecosystem

    The GABA-B Heterodimer Was Hiding in Plain Sight Dr. only survives translation if the coupling profile in the relevant human cells matches the cell-line model Marshall's caution is hard-won: many animal-model-validated GPCR drugs have failed in the clinic precisely wave of GPCR drug design 18:47 Which GPCR families pharma is chasing now — and why 21:23 Why animal model So can we now try and encourage the next cohort of people to be the main speakers at conferences?"

  • Dr. GPCR Board | Dr. GPCR Ecosystem

    Trejo’s research program is to gain a thorough and mechanistic understanding of processes that control critical expertise, and rigorous approaches to examine PAR1 function using human cultured cells and mouse models San Diego Supercomputer Center, and provided consultation for genetic sequence analysis, molecular modeling

  • Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems | Dr. GPCR Ecosystem

    Attendees will gain a technical understanding of probe design, selectivity, and validated applications masterclasses with leading researchers Structured networking for scientists and biotech professionals Nonprofit model

  • Dr. Roger Sunahara | Dr. GPCR Ecosystem

    His main area of research focuses on the structural and pharmacological bases for hormone-mediated activation The structure was first snapshot of the agonist- and G protein-bound GPCR, providing valuable models We have identified several GPCR ligands that allosterically modulate orthosteric ligand binding and target

  • Paul Insel: Unbiased Discovery and the GPCRs We've Been Missing | Dr. GPCR Ecosystem

    Listeners will gain perspective on how asking broader questions about receptor biology can reshape drug combines bioinformatic analysis of GPCR expression across human cancers with wet-lab validation in animal models studied receptor function in human physiology, receptor molecular pharmacology in cells, and animal models

  • Yamina's Corner | Dr. GPCR Ecosystem

    Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic Organizations Elevate Scientific Offerings: Refine and optimize your GPCR assay platforms and in vitro models We made confident progress on a pivotal program and gained clarity on our next strategic focus.

  • Qing Fan: Inside the Architecture of Class C GPCRs | Dr. GPCR Ecosystem

    each transmembrane bundle that appear to function as both structural anchors and negative allosteric modulators analysis of the GABA-B2-bound lipid site further suggested that lipid acts as a negative allosteric modulator allosteric sites within the transmembrane domain as a more targeted alternative: they offer receptor modulation inside each transmembrane bundle 12:55 - What the lipids actually do - structural components, allosteric modulation , and open questions 14:57 - Disease territory: epilepsy, spasticity, pain, addiction, and the limitations

  • GPCR Webinars | Dr. GPCR Ecosystem

    David Hodson Topics Covered: LUXendin probes for GLP-1R labeling across imaging modalities daLUXendin Each session explores mechanistic models, translational challenges, and real-world therapeutic implications GPCR pharmacology, signaling, structural biology, allosteric modulation, biased agonism, assay design

  • Affiliate Policy | Dr. GPCR Ecosystem

    GPCR to gain access to the Affiliate Program. Commissions are paid on qualifying sales made through the affiliate's unique links. Commissions are not paid on sales that are canceled. GPCR pays affiliates via a PayPal account, provided to us when a member joins. Paid Search Dr. GPCR maintains a strict policy on paid search activity.

  • FAQ | Dr. GPCR Ecosystem

    Each session explores mechanistic models, translational challenges, and real-world therapeutic implications These GPCR webinars focus on conceptual frameworks, models, and translational insight that apply across introduce key concepts, the overall level is advanced and assumes familiarity with pharmacological models Topics may include: Receptor efficacy and operational models Allosteric modulators (PAMs and NAMs) Biased They provide exposure to current thinking, advanced modeling approaches, and expert interpretation of

  • Brian Bender: Computational Probes for Orphan GPCR | Dr. GPCR Ecosystem

    At UCSF, he develops structural models of GPCRs using sparse experimental data - combining restraints His fluency in both bench and computational languages shapes how he builds models and how he interprets Rather than a setback, it became a forced pivot into computation at precisely the moment his modeling Bench experience as a modeling guardrail Knowing what an EC50 means experimentally, or what a Bmax implies Bender credits his time at the bench with preventing the kind of over-interpretation that models built

  • Antonella Di Pizio: Computational Pharmacology of Taste and Olfactory Receptors | Dr. GPCR Ecosystem

    Antonella Di Pizio on building computational models for GPCRs with almost no crystal structures and almost TAARs look more classical than most chemosensory GPCRs — and that matters for modeling. Di Pizio's workflow is deliberately iterative: build the model, predict binding-site residues, send them out for mutagenesis, fold the experimental results back into the model, rebuild. Collaborators are not recipients of finished predictions — they are partners embedded in the modeling

  • Maria Waldhoer: Pharmacological Fingerprints and the Limits of Bias | Dr. GPCR Ecosystem

    Her team at InterAx models receptor signaling pathways as systems of time-dependent equations, then runs kinetic assays to refine the models and extract ten to fifteen pharmacological parameters from what Model first, pipette second. InterAx treats GPCR pharmacology the way engineers treat aircraft design: build the mathematical model signaling pathways first, then use controlled kinetic assays as the "wind tunnel" that refines the model

  • Ross Cheloha: Nanobody-GPCR Conjugates and the Engineering of Receptor Selectivity | Dr. GPCR Ecosystem

    In this conversation, he describes how attaching a moderately active peptide to a receptor-targeted nanobody The working model is that the nanobody anchors the conjugate at the receptor surface, positioning the camelid nanobodies 25:45 The first nanobody-GPCR ligand conjugate and an unexpected 10,000-fold potency gain

  • Beatriz Blanco-Redondo: Adhesion GPCR Discovery in Drosophila | Dr. GPCR Ecosystem

    a human ortholog linked to vascular malformations and blood-brain barrier dysfunction in vertebrate models completing her PhD in Germany and her postdoctoral work at Columbia University, where she worked on ALS models adhesion GPCR research in Drosophila, CRISPR, epitope tagging, and knockout strategies The logic of model ortholog has been associated with vascular malformations and blood-brain barrier dysfunction in vertebrate models That thread, from a behavioral assay in a fly larva to a clinical phenotype in mice, is what gives the model

  • Exploring Career Paths in GPCR Research with Dr. Jacek MokrosiĹ„ski | Dr. GPCR Ecosystem

    mechanism through which rare genetic variation may lead to or protecting from excessive body weight gain Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations

  • Michel Bouvier: BRET, Biased Agonism, and the Tools That Changed GPCR Pharmacology | Dr. GPCR Ecosystem

    Tools That Changed GPCR Pharmacology G-protein-coupled receptors were once described through a simple model The model was clean, teachable, and wrong in ways that took decades to prove. SCIENTIFIC THEMES OF THE CONVERSATION The limits of the binary receptor model and what inverse agonism Every receptor his lab has studied was selected because it was the right model for a question that was The divide illustrated something Bouvier has observed repeatedly: mental models, once useful, can become

  • Dr. Thomas P. Sakmar | Dr. GPCR Ecosystem

    strategies to express, reconstitute and assay engineered GPCRs using the visual pigment rhodopsin as a model that stemmed from this work, such as the concept of “functional micro-domains” and the “helix movement model Tom’s lab also pioneered the early use of computational homology modeling, molecular dynamics simulations

  • Why Mosquitoes Hunt You: GPCR Control of Blood Feeding and Mating | Dr. GPCR Ecosystem

    Duvall emphasizes the value of model systems and cross-species discoveries in GPCR biology. If you often translate receptor mechanism findings from model organisms to human systems. If you want to expand high-throughput or fluorescence-based assay strategies to non-traditional models Pew Scholarship, she continues to drive efforts to decode how evolutionarily conserved GPCR pathways modulate

bottom of page